CAS 1088715-84-7

LY2510924

CAS : 1088715-84-7

Formule : C₆₂H₈₈N₁₄O₁₀

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 1189.4499

Ref: IN-DA01EOL6

(2S,5S,8S,11R,14S,20R)-N-((S)-1-Amino-6-(isopropylamino)-1-oxohexan-2-yl)-2-benzyl-11-(3-guanidinopropyl)-5-(4-hydroxybenzyl)-8-(4-(isopropylamino)butyl)-14-(naphthalen-2-ylmethyl)-3,6,9,12,15,18,23-h

CAS : 1088715-84-7

(2S,5S,8S,11R,14S,20R)-N-((S)-1-Amino-6-(isopropylamino)-1-oxohexan-2-yl)-2-benzyl-11-(3-guanidinopropyl)-5-(4-hydroxybenzyl)-8-(4-(isopropylamino)butyl)-14-(naphthalen-2-ylmethyl)-3,6,9,12,15,18,23-h

Degré de pureté : 98%

Masse moléculaire : 1189.47g/mol

Ref: 54-OR1074817

LY2510924

CAS : 1088715-84-7

LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM).

Formule : C₆₂H₈₈N₁₄O₁₀

Couleur et forme : Solid

Masse moléculaire : 1189.45

Ref: TM-T15805

LY2510924

CAS : 1088715-84-7

LY2510924 is a small molecule chemokine antagonist that inhibits the binding of chemokines to their receptors. It has been shown to have potent in vivo efficacy against infectious diseases in combination with other drugs, such as monoclonal antibody and cyclic peptide. LY2510924 also inhibits the growth of cancer cells by inhibiting the production of growth factors and mesenchymal markers. This drug has been shown to bind to cxcr4, which is a receptor for chemokines CCL2, CCL7, and CCL12. LY2510924 does not have any effect on prostate cancer cell proliferation or migration in vitro assays.

Formule : C₆₂H₈₈N₁₄O₁₀

Degré de pureté : Min. 95%

Masse moléculaire : 1,189.45 g/mol

Ref: 3D-NTB71584